INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Recommendation of “Buy” by Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been given a consensus recommendation of “Buy” by the six analysts that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $22.80.

A number of analysts recently commented on the company. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Rodman & Renshaw assumed coverage on INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price target for the company. Maxim Group lifted their target price on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, Scotiabank boosted their target price on shares of INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Tuesday, February 11th.

Institutional Investors Weigh In On INmune Bio

Several hedge funds and other institutional investors have recently modified their holdings of INMB. Wells Fargo & Company MN increased its stake in INmune Bio by 51.0% in the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after purchasing an additional 2,155 shares during the period. Beacon Pointe Advisors LLC bought a new position in shares of INmune Bio during the 4th quarter worth $48,000. JPMorgan Chase & Co. raised its holdings in shares of INmune Bio by 93.0% in the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after acquiring an additional 5,461 shares in the last quarter. Two Sigma Advisers LP purchased a new position in INmune Bio during the 4th quarter valued at about $59,000. Finally, Mariner LLC purchased a new position in INmune Bio during the 4th quarter valued at about $65,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

INmune Bio Price Performance

NASDAQ INMB opened at $6.84 on Friday. The stock has a market capitalization of $156.84 million, a price-to-earnings ratio of -3.14 and a beta of 1.86. INmune Bio has a one year low of $4.32 and a one year high of $12.72. The business’s fifty day moving average is $8.36 and its 200-day moving average is $6.49.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.14. Research analysts expect that INmune Bio will post -2.24 EPS for the current fiscal year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.